Loading, Please Wait...
BOSTON, MA--(Marketwired - Mar 3, 2016) - Solos Endoscopy, Inc. (
Solos Endoscopy instruments are registered and approved with the FDA; the FDA approval also covers the entire MammoView® instrument line. The company markets over 200 items to the endoscopic market and is continuing the development of products that will enhance the ability of medical professionals to perform minimally invasive surgical techniques.
Solos Endoscopy recently completed a capital restructuring initiative in order to position itself for growth over the next twelve months. The Company plans to raise capital in order to fulfill outstanding purchase orders and pursue international sales initiatives.
"Management believes that renewal of its establishment registration with the FDA along with the capital restructuring was necessary to maintain the value of our company and position us for growth. Solos has been recognized nationwide by physicians who use their instruments. It is our hope that this recognition will lead to increased sales worldwide," stated Robert Segersten, President of Solos Endoscopy.
About Solos Endoscopy, Inc.:
Solos Endoscopy recently celebrated its 25th Year of providing quality innovative healthcare instruments to Hospitals across the Country. For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
Solos Endoscopy, Inc.